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Abstract: Absorbed collagen sponge (ACS)/bone morphogenetic protein-2 (BMP-2) are widely used
in clinical practise for bone regeneration. However, the application of this product was found to
be associated with a significant pro-inflammatory response, particularly in the early phase after
implantation. This study aimed to clarify if the pro-inflammatory activities, associated with BMP-2
added to ACS, were related to the physical state of the carrier itself, i.e., a wet or a highly dehydrated
state of the ACS, to the local degree of vascularisation and/or to local biomechanical factors.
ACS (0.8 cm diameter)/BMP-2 were implanted subcutaneously in the back of 12 eight-week-old
Sprague Dawley rats. Two days after surgery, the implanted materials were retrieved and analysed
histologically and histomorphometrically. The acute inflammatory response following implantation
of ACS was dependent of neither the presence or absence of BMP-2 nor the degree of vascularization
in the surrounding tissue nor the hydration state (wet versus dry) of the ACS material at the
time of implantation. Differential micro biomechanical factors operating at the implantation site
appeared to have an influence on the thickness of inflammation. We conclude that the degree of the
early inflammatory response of the ACS/BMP-2 may be associated with the physical and chemical
properties of the carrier material itself.
Keywords: bone morphogenetic protein-2 (BMP-2); absorbed collagen sponge (ACS); inflammation;
vascularization; biomechanical
1. Introduction
Recombinant human bone morphogenetic protein-2 (BMP-2), a member of the transforming
growth factor beta (TGF-β) superfamily, is in clinical use since more than a decade [1,2]. It is used
in clinical practice for spinal fusion [3] and for treatment of non-unions to enhance bone formation
processes and to accelerate the bony healing response; in dental practice it is used for oral and
maxillofacial reconstruction [4,5].
Even though the clinical use of BMP-2 is very successful, its clinical application is associated with
some serious unwanted effects such as heterotopic bone formation [6], bone resorption (by osteoclast
activation) and formation of cyst-like bone voids [7], as well as postoperative inflammatory
swelling [8,9] and neurological symptoms, etc.
BMP-2 is clinically applied as a free factor (Infuse® (USA), Inductos® (Europe)) together with
an ACS as a carrier. BMP-2 of this product is used in very high dosage, and it is believed that it is
this high dosage level of BMP-2 that leads to extensive inflammatory responses. This use-associated
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inflammation is one of the main reasons why several of the above-described unwanted effects do
occur. It is also believed by many authors that BMP-2 itself contributes significantly to the enhancing
of the inflammatory response during and after the implantation of the construct in this kind of a tissue
engineering approach. Indeed, several publications report that BMP-2 itself enhances the swelling
and the inflammatory response in the surrounding soft tissues in conjunction with the carrier material
(ACS) [10].
Seroma formation is, for example, a frequently observed side effect of BMP-2-use, encountered
most commonly in the first week postoperatively, as described in several studies [8,11].
Rihnet et al. [12] found that lumbar seromas occurred in 1.2% of rhBMP-2 treated patients compared
to 0% in the control patient population. Robin et al. [8] described postoperative seroma formations
associated with BMP-2 use in the surrounding soft tissues in the cervical region that led to bilateral
paresthesia of the upper extremities. In clinical cases with BMP-2-induced seromas, elevated serum
levels of inflammatory cytokines were found, such as those of IL-6, IL-8, and TNF-α [13], as well as
those of IL-10 [10].
Indeed in the publication of Lee et al. [10], a dose-dependency of the inflammatory response
to high dosage levels of BMP-2 was found. However, in a report of Wu et al. [14] it was described
that BMP-2, in particular when delivered in a slow release system, is able to attenuate inflammatory
responses. In other in vivo animal experiments [15], microcomputed tomography and histological
analyses confirmed that PCL/PLGA/collagen/rhBMP-2 scaffolds (long-term delivery mode) showed
the best bone healing quality at both weeks 4 and 8 after implantation without inflammatory response.
Thus, conflicting data are encountered in the scientific literature respecting the role of BMP-2 and it
use-associated inflammation.
The purpose of this study was to investigate if the use of BMP-2, when applied at high
concentrations as a free factor together with a carrier material (ACS), is indeed associated with
a pro-inflammatory response in the acute phase of the body response, i.e., in the initial two days after
implantation of this growth factor with the carrier material. It is, indeed, conceivable that it is not
the BMP-2 itself that triggers the intensive inflammatory response, but that the inflammation may be
elicited by a number of other factors operating in close topographical vicinity to the deposited collagen
carrier. Such candidate factors may be the degree of tissue vascularity, or the local micromechanical
conditions of different physiological stress fields, i.e., depend on differences in the local biological
environment (differential niche biology). Another role may be played by the physical state in which
the collagen carrier itself is deposited, i.e., inserted in a dry state or in a wet state into the living
tissue spaces. Since burst release of BMP-2 (in surgical practise poured onto the ACS sponge) does
readily occur, among others due to mechanical manipulation of the construct itself during surgical
implantation [16], we set up in our experiments a specific control group in which the collagen carrier
was kept in a dry state to assess the possible role of such mechanical stress-modulated release profiles
of BMP-2 in the inflammatory response.
In order to clarify the possible role of these various candidate factors, the Sprague Dawley (SD)
rat was used as the animal model. ACS carrier material was implanted in the subcutaneous space in
the back area (lumbar level). By this set up the deposited collagen carrier patch is exposed on one
side towards the skin, where the skin muscles of the rat generate a continuous instability situation,
i.e., a high biomechanical instability [17]. On the opposite side of the collagen patch, facing the
large underlying lumber muscle package, a relatively stable micromechanical environment is present.
In addition, the two different biomechanical niches around these implants are also characterized
by specific differential densities of blood vessels. The differential blood vessel densities at these
two opposite locations (skin side versus lumbar body side) were quantified in this study in order to
elucidate their possible proinflammatory contribution.
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2. Results
Figure 1A–D illustrated that already on the 2nd day after implantation, all collagen implants were
surrounded by a capsule of inflamed tissue (delineated by a red line), and was highly vascularized.
The inflammatory response involved large numbers of macrophages around each of the implanted
collagen sponges (Figure 1E). The outer border of the inflammation border of the collagen implant was
delineated by a red line and the inner border of the inflammatory zone by a yellow line (Figure 1A–D).
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(p = 0.009) of BMP-2. 
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body side) were quantified in this study in order to elucidate their possible role to contribute to the 
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was significantly higher than that on the skin side (p = 0.014) but no significance was found in the wet 
Figure 1. Microscopic findings following subcutaneous i plantation of: (A) dry Absorbed Collagen
Sponge (ACS); (B) dry bone morphogenetic tein-2 (BMP-2)/ACS; (C) wet ACS; (D) wet ACS/BMP-2;
(E) high magnification of i fl zone. ed ar ow: macrophage. The inflam atory zone was
delineated by two different lines: the outer border in red, the inner border in yello . Bar = 500 µ
(in A–D). The upper side is skin side and the lower side is lumber body side. Numerous macrophages
were identified in the highly vascularized inflamed zone (cf. 1E, bar = 20 µm).
The degree of inflammation activity was gauged by estimation of the volume of the implanted
sample and the volume of the inflamed tissue. As Figures 2 and 3 showed, the volumes of the implanted
collagen sample and the inflammation area were increased when the carrier (ACS) was loaded with
BMP-2. However, there were no significant differences observed between the collagen sponge volumes
in the presence or absence of BMP-2, nor if implanted in a wet or a dry (dehydrated) state.
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Figure 2. Mean volumes of collagen implants. No significant differences were found between dry ACS
and dry ACS/BMP-2 nor between wet ACS and wet ACS/BMP-2. Data were present as Means ± SEM.
n.s.: no significant difference.
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Figure 3. Periimplant inflammation volume. No significant differences were found between dry ACS
and dry ACS/BMP-2 nor between wet ACS and wet ACS/BMP-2. Data were present as Means ± SEM.
n.s.: no significant difference.
As Figure 4 illustrates, the mean thickness of the inflamed tissue at the skin side and the lumbar
body side is different, and significant differences were indeed found around the dry ACS implants in
the absence of BMP-2 (p = 0.001), and in the wet ACS groups in the presence (p = 0.0009) or absence
(p = 0.009) of BMP-2.
The differential blood vessel densities at these two opposite locations (skin side versus lumbar
body side) were quantified in this study in order to elucidate their possible role to contribute to the
proinflammatory response. As Figure 5 shows, the area density of blood vessels on both sides were
different, the area density of blood vessels in the dry group without BMP-2 on the lumbar body side
was significantly higher than that on the skin side (p = 0.014) but no significance was found in the
wet group. In the group with BMP-2, the area density of blood vessels in the dry group was found to
be higher on the lumbar body side than on the skin side, but was not significantly different (due to
a high degree of variation; cf. SEM-error bar in Figure 5), in the wet group, the area density of blood
vessels on the lumbar body side was significantly higher than that on the skin side (p = 0.032). Figure 6
illustrates typical areas and blood vessel densities as encountered on the skin side (Figure 6A,C) and
the lumbar body side (Figure 6B,D).
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Figure 4. Comparison of the mean thickness of the inflammation zone on the skin side and the body
side. There are significant differences in the thickness of the inflammatory zones between the skin side
and the lumbar body side in the dry ACS implant group without BMP-2, and in both the wet ACS
groups with or without BMP-2. **: p < 0.01, ***: p < 0.001, n.s.: no significant difference.
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Figure 5. Area density of blood vessels in the dry and wet ACS implant groups, comparing the skin
side blood vessel density with the lumbar body side blood vessel density. The data reveal that the
density is significantly different physiologically. *: p < 0.05, n.s.: no significant difference.
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6. Illustration of blood v ssel density in the inflam d rea at the skin side (A,C) and the
lumbar body side (B,D) from the dry (A,B) and wet (C,D) ACS. Arrows point to selected blood v s els.
I: inflammation area. Bar = 100 µm. Red arrows: blood vessels.
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3. Discussion
This study is focusing on the initial response of the tissue to the implantation of a sterile scaffold
i.e., collagen matrix scaffold, available commercially for use in human patients.
The acute phase of inflammation within the two initial days after implantation is a sterile type
of inflammation in the absence of an infection. It is a non-specific tissue response to the foreign
body material implanted (carriers, biomaterials) [18]. Moreover, it is associated with tissue swelling,
formation of edema as well as the influx of a cell population of the acute inflammatory response type,
represented mainly by macrophages, and later on by foreign body giant cells [19]. This inflammatory
response is not to be confused with infection, which is caused by foreign agents such as bacteria,
viruses, etc. In this study, no infection was observed, and the inflammatory responses were all sterile
in nature.
The comparison between wet ACS and dry ACS implanted in the subcutaneously space of rats
revealed no difference in extent of inflammation in the acute phase (Figure 3). In addition, the sample
size of the ACS, implanted the same way in all experimental groups, exhibited no differences occurring
during these two early postimplantation days, i.e., no differences in early degradation activities
(Figure 2); also the degree of inflammation, quantified by the inflammation volume around the
implanted materials (Figure 3) during this acute inflammation phase did not reveal any significant
differences between the control group and ACS/BMP-2 groups. These findings indicate that the acute
inflammatory response in such cases is most likely based on the non-specific tissue reactions to foreign
materials placed into the body, and it is not dependent on other factors in its extent.
In particular, the comparison between the extent of inflammation in topographically different areas
such as the skin area compared to the lumbar body area, which are subjected to different biomechanical
stress fields [17], and also to different degrees of vascularity (Figures 5 and 6), that both physiologically
do occur at these sites, revealed no differences in the extent of the inflammatory response (Figure 3).
This basically implies that the degree of vascularity is irrelevant respecting the extent of the acute
inflammation response that can be expected following implantation of foreign materials into the body.
The same applies to the state of the hydration of the implant material which is similarly irrelevant to the
acute inflammation response with these materials i.e., implanted in a wet hydrated state or implanted
into the body in a dry state. Due to the absence of the difference in the inflammatory response in 2 days
it is probably implied that the dry material implanted get hydrated very rapidly inside the body so
that no difference in inflammatory response can be monitored. However, the thickness of the local
inflammation appeared quite irregular in the groups carrying BMP-2, represented by larger coefficient
of variation (Figure 5) (dry ACS/BMP-2 group: coefficient of variation (CV) = 100%, coefficient of error
(CE) = 45%) The thickness of the local inflammatory response was thus the only factor identified to
show any differences between the two chosen topographical locations (skin versus lumbar body), and
was thus associated with an asymmetrical response and a high degree of variation (dry ACS/BMP-2
group: CV = 100%, CE = 45%). This finding maybe a consequence of the angiogenetic activity of
BMP-2 that has been proved previously by various authors [20–22], and may be related to a more rapid
formation of blood vessels during the inflammation response when BMP-2 is present, and thus lead
to the observed high irregularity of the extent of the inflammatory response. However, as a whole,
the total inflammatory response remains the same in all experimental groups (Figure 3).
In the literature, it is described that in the subcutaneous tissue of rats, close to the skin, this area
is biomechanically very instable, due to continuous skin muscle activities which are associated
with irregular mechanical forces to occur, whereas in deeper areas near the lumber spine muscles,
less biomechanical instability is present in the associated tissues [17]; thus, the implanted materials are
physiologically exposed at the skin side and at the lumbar body side to differential mechanical force
fields with differential instability conditions. However, no major difference were observed respecting
the extent of inflammation around the implanted materials at the different site, minor differences
respecting thickness of local inflammation and its variance was found to be different. The most
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surprising finding in this study is the fact that the presence or absence of BMP-2 has no effect on the
extent of the initial acute inflammatory response.
From studies in various animal models, BMPs are known to have species-specific osteoinductive
dose requirements [23]. For example, in 2002, ACS/rhBMP-2 was FDA-approved as an autograft
replacement for interbody spinal fusion procedures in human patients (at a concentration of
1.5 mg/cc) [24]. The BMP-2 concentration necessary for inducing consistent bone formation is
substantially higher in nonhuman primates (0.75–2.0 mg/mL) than in rodents (0.02–0.4 mg/mL) [23].
In a recent publication, Luginbuehl et al. [25] found that 25 µg/mL in rodents, 50 µg/mL in
dogs, 100 µg/mL in non-human primates and 800 µg/mL in humans, are quite different optimal
osteoinductive BMP-2 concentrations, compared to the presently use clinical setting (0.75 and
1.5 mg/mL BMP-2) [26].
In a study of Lee et al. [10], the total amounts of BMP-2 used were 10 and 20 µg, and were
diluted to 1 and 2 mg/mL, for addition to the ACS carrier, and resulted in a final BMP-2 /ACS carrier
concentration of 3.3 and 6.67 mg/g for use. These authors found the inflammatory response to this
construct not only to be dependent on the presence of BMP-2, but also proportionally related to
its concentration. In our study, we used a total BMP-2 amount of 20 µg, dissolved and diluted to
1 mg/mL, and resulting in an ACS/BMP-2 carrier concentration of 10 mg/g, i.e., used BMP-2 in the
same order of magnitude. However, we were unable to observe any additional pro-inflammatory
response by the presence of BMP-2, as described by other authors [10,27]. Thus we conclude that the
primary factors leading to the inflammatory response in the body are actually associated with the
carrier itself and its chemical properties, but not to the presence of BMP-2. The materials used and
the experimental conditions chosen in our study were the same (BMP-2, collagen) or quite similar
(experimental conditions) to these previous studies [10].
It was interesting to find that in the different local areas (skin vs. lumbar body site), the thickness
of the inflammatory response was indeed significantly different (Figure 4) and/or of high variability
(see discussion above). We hypothesized that at sites of higher blood vessel densities on body side,
we would expect more inflammation to occur, since inflammatory responses are dependent on the
presence of an extensive blood vasculature, and would expect less inflammation at sites where the
blood vessel density is lower. Since this was not the case in our study (see Figure 5), and this
factor obviously overpowered by another biological influence, we attribute this finding to a higher
biomechanical stability condition on the site with thicker inflammatory response, i.e., on the skin side.
As Figure 5 illustrates in the group with dehydrated collagen sponges without BMP-2 and wet collagen
sponges with BMP-2, the blood vessel density at the body side is significantly higher than that of the
skin side. In the group with a dehydrated collagen sponge with BMP-2 and wet collagen sponges
without BMP-2, the thickness of the inflammation zone between these two topographical sites did
not show a significant difference, which would not be expected if the suggested hypothesis would
be operative. The difference in inflammation thickness may thus be related to other factors, such as
discussed above and in a recent review article of James et al. [5], in which the authors describe that
specific anatomic locations can be associated with distinctive adverse events to implanted materials.
We thus conclude that according to our experimental findings the use of BMP-2 is not associated
with the enhancement of pro-inflammatory effects in the initial phase of scaffold material implantation.
The acute inflammatory response appears to be triggered predominately by the carrier material
itself, its chemistry and physical properties, irrespective of the presence of BMP-2 or its absence.
The aforementioned unwanted side effects, such as postoperative inflammatory swelling [8,9],
possibly attribute to the carrier material itself, not by the BMP-2. As for a surgeon, should be very
careful to select an optimal carrier for BMP-2. Given the fact that BMP-2 has been described by
several authors to have an attenuating effect on inflammatory responses in the later phases of the
implantations [14], it is actually not surprising that we are unable to confirm that BMP-2 would have
a pro-inflammatory function.
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4. Materials and Methods
4.1. Animal Preparation
Twelve eight-week-old male SD rats (mean weight 230 g, range from 190–250 g) were used in
this study and divided into 4 experimental groups (n = 6 samples per group). ACSs (Medtronic
Sofamor Danek, Memphis, TN, USA) were cut into identically sized circular samples (8 mm diameter).
The experimental groups were defined as follows: Group1: ACS + 20 µL sterile water, group 2:
ACS + 20 µL BMP-2 solution containing 20 µg BMP-2 (The dosage of BMP-2 was determined as
previously described [10]); the samples of these two groups were stored under aseptic conditions
overnight. Group 3: ACS + 20 µL sterile water and group 4: ACS + 20 µL BMP-2 were prepared freshly
before surgery.
For induction of a general anesthesia 3% pentobarbital were intraperitoneally injected.
Aseptic techniques were used during the surgical procedures. The iliac crest was used as the landmark
for determining the location of the skin incision, a 25 mm posterior longitudinal incision was made
bilaterally, 5–10 mm laterally from the midline. ACSs were implanted with or without BMP-2 into the
subcutaneous space of the lumbar back. Right after implantation, the soft tissues were repositioned
and the wound was closed using standard non-resorbable suture materials. The wound was then
disinfected with 10% povidone-iodine. Animals were kept at 23 ◦C ambient temperature conditions
until awakening.
4.2. Animal Husbandry
The SD rats were kept in animal experiment center (Zhejiang Chinese Medical University
Laboratory Animal Research Center, Hangzhou, China). Temperature for keeping the SD rats was
18–23 centigrade, day/night light cycle time were 14/10 (h/h), humidity 60%–80%, sterile complete
feed(Anlimo, Nanjing, China) and filtered water were freely available.
4.3. Tissue Processing
The rats were sacrificed on postoperative day 2, at which point the collagen samples were
retrieved with the adhering/surrounding tissues and chemically fixed in buffered 10% formaldehyde
solution [17] for 1 day at ambient temperature, they were rinsed in tap water, dehydrated in ethanol
and embedded in methylmethacrylate [14]. Using a Leica diamond saw (Leco VC-50, St. Joseph,
MO, USA), the tissue blocks were cut into 5–7 slices, 600-µm-thick and 1mm apart, according to
a systematic random sampling protocol [28]. All slices were then glued to plastic specimen holders and
ground down to a final thickness of 80–100 µm. They were then surface-polished and surface-stained
with McNeal’s Tetrachrome, basic Fuchsine and Toluidine blue, according to the publication of
Schenk et al. [29].
4.4. Histomorphometry
4.4.1. Sample Volume and Volume of Inflammation
The sections were photographed at a final magnification of ×40 in a Nikon light microscope
(Eclipse 50i Microscope, Tokyo, Japan), and photographic subsampling performed according to
a systematic random-sampling protocol [28]. Using the photographic prints, the volume of the implants
and the inflammation areas (associated with each sample) were determined by point counting [30],
respecting stereological principles. The final volumes were estimated using Cavalieri’s principle [28].
4.4.2. Thickness of Inflammation Volume
It was visually observed that the inflammation thickness of the periimplant inflammation zone
was different when comparing the skin side and lumber body side areas. It therefore was decided to
measure the thickness of the skin side and the opposite location at the body side by drawing parallel
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lines across the sample and vertically to its surface; thickness measurements were performed along
these lines between the implant surface boundary and the end of the inflammation zone.
4.4.3. Blood Vessel Density
In dry ACS and ACS/BMP-2 group, using the photographic prints (magnification ×40), areas for
high magnification imaging (×200) were chosen according to a systematic random protocol to be
photographed and for morphometrical determination of the area density of blood vessels, again both
on the skin side and on the opposite body side [28].
4.4.4. Statistical Analysis
Independent t-tests were applied to the data to obtain specific comparisons between experimental
and control groups of the histomorphometrical data. All statistical analyses were performed with
SPSS® 21.0 software (SPSS, Chicago, IL, USA), and statistical significance was defined as p < 0.05.
5. Conclusions
It is the collagen carrier itself that is the determining factor in eliciting and regulating the degree
of the inflammatory response in the acute phase after implantation of an ACS/BMP-2 carrier construct
in the bodily environment. This finding suggests that further development and optimization of the
carrier material may be a promising way to reduce in the future the incidence and extent of the
early inflammatory response as an unwanted side-effect in the soft tissue reactions around this type
of implants.
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